Drug Profile

Onzotrigine - Latigo Biotherapeutics

Alternative Names: LTG-001

Latest Information Update: 08 Sep 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Latigo Biotherapeutics
Class Non-opioid analgesics; Small molecules
Mechanism of Action Nav1.8 voltage-gated sodium channel inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase II Postoperative pain
Phase I Acute pain

Most Recent Events

04 Sep 2026 Latigo Biotherapeutics plans two phase III trials for Acute pain (PO), in the second half of 2026
03 Sep 2026 Preclinical trials in Acute pain in USA (IV), prior to September 2026
03 Sep 2026 Latigo Biotherapeutics seeks regulatory feedback on the clinical development strategy for an intravenous formulation

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com